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scriptions and were mainly dermatological and liquid
preparations.
The table shows the official labelling of drugs
prescribed for children. In 21.3% of the prescriptions
for licensed drugs, use in children was not mentioned
in the summary, and 19.7% mentioned use in children
but without any indication of age. Although the
summaries of remaining drugs indicated age, children
were often divided into just two age groups.
Overall, 22.7% (15 453) of the prescriptions for
children were used off label. Drug groups with the
highest percentages of off label use were urologicals or
sex hormones (mainly oral contraceptives; 85.9%),
ophthalmological and otological drugs (79.4%), der›
matological drugs (55.9%), and cardiovascular drugs
(48.3%). In the group with the highest number of
prescriptions—respiratory drugs—16.1% of all pre›
scriptions were used off label.
Comment
Many licensed drugs used by children in the community
are poorly labelled for use in children, resulting in high
percentages of off label use. Therefore labelling for
children needs to be improved, with the support of
everyone working in pharmacotherapy.
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Drugs are subject to licensing procedures to ensure
their quality, efficacy, and safety, but many drugs used
to treat children in hospital are either not licensed for
use in children (“unlicensed”) or are prescribed outside
the terms of the product licence (“off label”).1 Little is
known about such prescribing in general practice, so
we conducted a cohort study in primary care in the
Netherlands to investigate the subject.
Methods and results
We retrieved data from the integrated primary care
information project, a longitudinal observational data›
base containing information from computer based
patient records of 150 general practitioners in the
Netherlands. The system complies with European
Union guidelines on the use of medical data for medi›
cal research and has been proved valid for pharma›
coepidemiological research.2
Within the dynamic population of children (0›16
years) registered in 1998, we conducted a one year
population based cohort study. From a source popula›
tion of 53 702 eligible children, we randomly sampled
25% (n=13 426; 6941 (51.7%) boys), which formed our
final study population. During the year 8271 (61.6%)
children consulted their general practitioner at least
once; the median was one consultation a year. We clas›
sified all 17 453 drug prescriptions issued to 6141
(45.7%) children according to the licensing status of
the drug,1 by reference to the official product licence, as
provided by the Dutch Medicines Evaluation Board.
Seventy one per cent (12 405) of prescriptions were
for drugs licensed for use in children and prescribed in
agreement with the product licence. Of the remaining
5048 (28.9%) prescriptions, 2667 (15.3%, 95% confi›
Information given in summary of product characteristics of drugs prescribed to children in the community in the Netherlands
Category Example
No (%) of summaries
(n=1421)
No (%) of prescriptions
(n=56 731)
Child mentioned with indication of age Children 2›5 years: 10 mg per day 653 (46.0) 32 180 (56.7)
Child not mentioned Only “patients” in general mentioned 302 (21.3) 11 688 (20.6)
Child mentioned without indication of age Children: 0.75 mg/kg in twice daily 280 (19.7) 11 108 (19.6)
Child mentioned but advised against use for all ages Should not be used in children; safety and
efficacy have not been established in children
140 (1.0) 1 328 (2.3)
Child mentioned and age estimated on basis of description Adults and older children: 10 mg per day 19 (1.3) 219 (0.4)
Child mentioned and age estimated on basis of weight Children >30 kg: 10 mg per day 13 (9.9) 130 (0.2)
Summary of product characteristics not available 14 (1.0) 78 (0.1)
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dence interval 14.8% to 15.8%) were for drugs not
licensed for use in children and 2381 (13.6%, 13.1% to
14.2%) were off label prescriptions for licensed drugs
(table). The drugs most often prescribed unlicensed or
off label were fusidic acid (ophthalmological gel), salb›
utamol (aerosol), deptropine citrate, amoxicillin, and
fluticasone (aerosol). The baseline risk of receiving one
or more unlicensed or off label prescription was 45.5%
(44.3% to 46.8%) for children who received at least one
prescription during the study period. The risk was 18%
(10% to 26%) higher for girls than for boys. Compared
with children aged 6›12 years, the relative risk of
receiving unlicensed or off label prescriptions was 2.6
(2.4 to 2.9) in children aged 6›24 months and 1.7 (1.6
to 1.9) in children aged 2›6 years. The overall risk of
receiving an unlicensed or off label prescription was
13.9% (13.5% to 14.3%) per consultation.
Comment
The absolute risk of prescription of unlicensed and off
label drugs in children was substantial in this Dutch
general practice setting. The risk is lower than
in secondary and tertiary care,1 but the potential
negative health impact of these findings should be
considered. Although unlicensed and off label
prescribed drugs do not necessarily carry an actual
threat to the health of a child, the risk of adverse drug
reactions is high, as adequate dosing schemes have
often not been assessed.3 For instance, bone deminer›
alisation and impairment of growth may follow long
term use of respiratory corticosteroids in children.4
Similarly, the use of highly dosed deptropine citrate in
small children can cause hallucinations, agitation,
ataxia, and anxiety.5
A considerable number of drugs prescribed to
children in general practice are not licensed for use in
children or are prescribed off label. Unlicensed and off
label prescription of drugs in general practice is less
frequent than in a clinical care setting but is still
substantial, especially as the absolute number of
children using such drugs is much higher than
in secondary and tertiary care. This situation is
highly unsatisfactory, and efforts should be made to
improve it.
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Classification of drugs prescribed to children in primary care
Category
No (%)
(n=17 453)
Licensed for use in children 12 405 (71.1)
Off label* for:
Age 699 (4.0)
Dose 978 (5.6)
Frequency 279 (1.6)
Indication 565 (3.2)
Dosage form 190 (1.1)
Route of administration 4 (<0.1)
Total off label prescriptions 2 381 (13.6)
Unlicensed for use in children:
No information in product licence on use in children† 1 453 (8.3)
Contraindicated in children 152 (0.9)
Modified preparation‡ 1 062 (6.1)
New drugs 0
Total prescriptions for drugs unlicensed in children 2 667 (15.3)
*As drugs in off label category can be classified under more than one group,
totals add up to more than 2381 prescriptions.
†No information on use in children found in any subsection of product licence.
‡Drugs produced under a special manufacturing licence—have not been
subject to licensing regulations and therefore have no product licence.
A medical mishap
Caustic eye drops
A patient attending for day case cataract surgery had phenol drops instilled into the right eye instead
of bupivacaine local anaesthetic. Although bupivacaine is the only eye drop used in the day case
centre in this type of bottle, phenol is used topically by chiropodists. The similarity of the bottles
highlights the importance of reading a label before administration of a treatment. This mishap also
shows the need for cross specialty risk management when different departments use the same work
space. The caustic burn was treated successfully, and the patient eventually achieved good vision after
uncomplicated cataract surgery.
Austin G McCormick senior house officer, department of ophthalmology, Royal Hallamshire Hospital, Sheffield
We welcome articles of up to 600 words on topics such as A memorable patient, A paper that changed my
practice,My most unfortunate mistake, or any other piece conveying instruction, pathos, or humour. If
possible the article should be supplied on a disk. Permission is needed from the patient or a relative if
an identifiable patient is referred to. We also welcome contributions for “Endpieces,” consisting of
quotations of up to 80 words (but most are considerably shorter) from any source, ancient or modern,
which have appealed to the reader.
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